Morgan Stanley analyst Thomas Wrigglesworth lowered the firm’s price target on Novonesis (NVZMY) to DKK 560 from DKK 569 and keeps an Overweight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVZMY: